RxDoctor Payments Data

Bradley Gardner, MD

Ophthalmology · Idaho Falls, IDNPI 1255408217

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 46 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by Alcon at 54.4% of the total.

$1,295in general payments, 2019–2025

Across 46 payments — averaging $28.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$705
  • AbbVie$210
  • Johnson & Johnson Surgical Vision, Inc.$99
  • Sight Sciences, Inc.$88
  • Biotissue Holdings Inc.$56
  • Rxsight Inc$39
  • plus $98 from 4 others

What the payments were for

  • Food & beverage$1,295100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,295 in reported general payments places this provider in the 60th percentile of 60 ophthalmology providers in Idaho.

See all ophthalmology providers in Idaho

Medicare billing

Part B allowed, 2024
$440,363
Medicare patients
708
Services billed
2,071

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate221$6,977
LumiganBimatoprost12$5,959
SimbrinzaBrinzolamide/Brimonidine Tart14$2,688
Ciprofloxacin Hcl127$2,046
Ketorolac Tromethamine64$1,489
Brimonidine Tartrate17$939
Latanoprost65$748
Timolol Maleate34$328
Ofloxacin14$245
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat23$191
ErythromycinErythromycin Base14$126

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan$210$5,95912 claims
AlconSimbrinza$705$2,68814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 60 ophthalmology providers in Idaho.

Other ophthalmology in Idaho Falls

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →